You are now leaving the Lilly Medical website
The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
Click "Continue" to proceed or "Return" to return to Lilly Medical
If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Retatrutide-Obesity
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling.
What were the discontinuation rates due to adverse events in the retatrutide TRIUMPH trials in patients with overweight or obesity?
Across the TRIUMPH 1-4 trials, treatment discontinuation due to AEs ranged from 4% to 18% with retatrutide and 4% to 5% with placebo.
Content Overview
What were the discontinuation rates due to adverse events in each TRIUMPH trial?
Treatment discontinuation rates due to adverse events in the retatrutide TRIUMPH phase 3 clinical trials are presented in Table 1.
Table 1. Treatment Discontinuation Rates Due to Adverse Events in the Retatrutide TRIUMPH trials1-4
Trial (Population; Treatment Duration) |
Retatrutide 4 mg, % |
Retatrutide 9 mg, % |
Retatrutide 12 mg, % |
Placebo, % |
|---|---|---|---|---|
TRIUMPH-1 (obesity or overweight without T2D; 80 weeks) |
4 |
7 |
11 |
5 |
TRIUMPH-2 (obesity or overweight with T2D; 80 weeks) |
4 |
12 |
8 |
5 |
TRIUMPH-3 (obesity with established CVD, with or without T2D; 80 weeks) |
NA |
10 |
14 |
5 |
TRIUMPH-4 (obesity or overweight with knee osteoarthritis; 68 weeks) |
NA |
12 |
18 |
4 |
Notes: Values are percentages of participants who discontinued study treatment due to adverse events. Trial populations, treatment durations, and doses studied differed across trials; results are not intended for cross-trial comparison.
Abbreviations: CVD = cardiovascular disease; NA = not applicable (retatrutide 4 mg was not studied in TRIUMPH-3 or TRIUMPH-4); T2D = type 2 diabetes.
References
The published references below are available by contacting 1-800-LillyRx (1-800-545-5979).
- Jastreboff AM, Kaplan LM, Davies MJ, et al. Retatrutide, a triple hormone receptor agonist for treatment of obesity. N Engl J Med. Epub ahead of print September 29, 2026. https://doi.org/10.1056/NEJMoa2604169
- Bellido V, le Roux C, Ekinci E, et al. Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial. Lancet. Epub ahead of print September 29, 2026. https://doi.org/10.1016/S0140-6736(26)01861-1
- Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C. News release. Eli Lilly and Company; July 23, 2026. Accessed September 25, 2026. https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-successful-two-additional
- Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis in first successful Phase 3 trial. News release. Eli Lilly and Company; December 11, 2025. Accessed September 25, 2026. https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-weight-loss-average
Date of Last Review: September 25, 2026